RBC Capital analyst Leonid Timashev maintained a Hold rating on Exelixis on April 7 and set a price target of $43.00. The company’s shares closed yesterday at $43.99. Easter Sal ...
UnitedHealth (UNH) outlook: 2026 reset amid regulatory pressure; Medicare Advantage scale & value-based care could lift ...
Eli Lilly ( LLY) and Centessa Pharmaceuticals ( CNTA ), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions ...
Zacks Investment Research on MSN
Exelixis (EXEL) is a top-ranked value stock: Should you buy?
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
Zacks Investment Research on MSN
Here's why Exelixis (EXEL) is a strong growth stock
For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. Featuring daily updates ...
On March 2, 2026, Exelixis, Inc. (NASDAQ:EXEL) saw its price target from RBC Capital lowered from $46 to $43. The firm’s Sector Perform rating was maintained on the stock. In a research note, RBC ...
MARCH 2026 AT 9:30 PM EET. Exel Composites Plc has executed a reverse share split. Exel Composites Plc ("Company”) has on 27 Ma ...
In a report released today, from Jefferies maintained a Buy rating on Exelixis, with a price target of $47.00. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ...
Top insights from the latest market news from Tuesday, March 17, from The Motley Fool analysts on Team Rule Breakers and Team ...
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results